RPG Life Sciences working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY22 and earlierAlpha Plus
156.97×156.97×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
52.48×52.48×
127.85×127.85×
81.60×81.60×
1.71×1.75×
0.98×0.98×
0.49×0.49×
0.38×0.38×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

RPGLIFE₹2,844.00

RPG Life Sciences Limited

· Pharma & Health
₹ CrorePeersGUFICBIOGUJTHEMUNICHEMLABORCHPHARMASMSPHARMAFDCIOLCPINDSWFTLABMcap ₹4,703 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Inventory Days (DIO)———156.97156.97
Receivable Days (DSO)———52.4852.48
Payable Days (DPO)———127.85127.85
Cash Conversion Cycle (days)———81.6081.60
Working Capital Turnover———1.751.71
Asset Turnover———0.980.98
Cash Conversion (CFO/Net Income)———0.490.49
CFO/EBITDA———0.380.38
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.